Skip to main content

Table 1 Characteristics at diagnosis and follow-up for patients (N = 279), split by treatment group. Median values and range are reported for the groups

From: Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome

 CBCT+a MetS+bCBCT− MetS+CBCT+ MetS−CBCT− MetS−CBCT model p valueMetS model p value
N6134 (32c)11569  
Age at diagnosis (years)30 (18–52)30 (16–49)27 (16–47)28 (18–52)0.09< 0.001
Age at sample collection (years)48 (29–64)45 (28–74)44 (23–61)43 (26–62)0.81< 0.001
Age at survey II (years)51 (36–69)52 (36–68)47 (31–66)48 (33–68)0.06< 0.001
Time between surgery and sample collection (years)17 (5–27)18 (6–35)17 (6–28)14 (5–28)0.020.02
Time between sample collection and MetS diagnosis (years)0 (0–9)8 (− 8–9)0 (0–9)8 (0–9)<0.0010.09
Clinical characteristics at diagnosis
Initial disease stage    < 0.0010.58
I18323566  
IMK positived/II360583e  
III2040  
IV50180  
Histology    0.160.15
Seminoma8162  
Non-seminoma533110967  
Cumulative cisplatin dose (mg)790 (570–920) 760 (495–1400) < 0.001 
Selected characteristics at follow-up
Testosterone (nmol/L)f11.1 (3–26)12 (3–24)15 (3–32)16 (6–38)0.30< 0.001
Physical activity    0.400.002
Very active26127236  
Moderate25163728  
Sedentary10454  
Smoking status    0.770.13
Never smoker (%)43335149  
Former smoker (%)34422428  
Current smoker (%)23242423  
Mean β methylation0.620.620.620.620.210.71
  1. aCBCT cisplatin-based chemotherapy
  2. bMetS metabolic syndrome
  3. cN passed array filter quality
  4. dIMK marker positive
  5. eRendered tumor free by surgery alone
  6. fRegression analysis showed that testosterone level is (on average) 4.2 nmol/L lower in groups 1 and 2 (MetS+) compared with groups 3 and 4 (MetS−) when adjusted for age (p = 1.6 E-07)